2,2,3,5,6,6-hexamethylheptan-4-one

We are 2,2,3,5,6,6-hexamethylheptan-4-one CAS:25-97-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:2,2,3,5,6,6-hexamethylheptan-4-one
CAS.NO:25-97-8
Synonyms:2,2,3,5,6,6-hexamethylheptan-4-one
3,3-DIMETHYL-2-BUTYL KETONE
2,2,3,5,6,6-hexamethyl-4-heptanone
 
Physical and Chemical Properties:
Molecular Formula C13H26O
Molecular Weight 198.34500
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Triadimefon(CAS:43121-43-3)、Triadimenol(CAS:55219-65-3)、Diclobutrazol(CAS:75736-33-3)、Bitertanol(CAS:55179-31-2)、Uniconazole(CAS:83657-22-1) and Paclobutrazol(CAS:76738-62-0).

2,2,3,5,6,6-hexamethylheptan-4-one


Related News: From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.Ethyl 5-(piperazin-1-yl)benzofuran-2-carboxylate CAS:163521-20-8 From the perspective of the overall life cycle of generic drugs from R & D to sales, with the expiration of patents, the business model for the production and marketing of generic pharmaceutical raw materials has changed, demand has increased, business potential has been realized quickly, and gross profit margins have shown a downward trend.5464-78-8 We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally.4-cloro-3-nitrobencenosulfonamida CAS:97-09-6 This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?

Related Products
Product Name
4,4,5,5,5-Pentafluoro-1-pentanethiol View Details
4-[4-Fluoro-3-(1-piperazinylcarbonyl)benzyl]-1(2H)-phthalazinone View Details
3,4-Dimethoxyphenylboronic Acid View Details
(2S)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile manufacturer Bis(triphenylphosphine)palladium(II) chloride manufacturer 2,6-Dimethylpiperidine manufacturer 2-[[(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carbonyl]amino]acetic acid manufacturer (R)-2-(4-Hydroxy-6-methylnicotinamido)-2-(4-hydroxyphenyl)acetic acid manufacturer